Physician profile
John Rowda
NPI 1497865489
$2,069.52
in general payments reported to CMS, 2019-2025
24 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $143 · 2021: $298 · 2022: $449 · 2023: $297 · 2024: $402 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.56 | 2022-2024 | Durysta, Xen Glaucoma Treatment System |
| Alcon Vision LLC | $257.41 | 2019-2025 | Clareon, Eysuvis, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $217.61 | 2019-2024 | Cequa |
| Coopervision INC. | $190.05 | 2024-2025 | Misight Contact Lens, Biofinity Contact Lens |
| Kala Pharmaceuticals, INC. | $165.95 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $118.98 | 2021-2022 | |
| Ocular Therapeutix, INC. | $93.49 | 2022 | |
| Sight Sciences, INC. | $75.69 | 2020-2023 | Tearcare System |
| Astellas Pharma US INC | $64.70 | 2024 | Izervay |
| Allergan, INC. | $61.78 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $60.61 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $53.73 | 2019-2021 | |
| Dompe US, INC. | $48.76 | 2020-2024 | Oxervate |
| Apellis Pharmaceuticals, INC. | $47.73 | 2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.39 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $42.92 | 2024-2025 | Xiidra, Miebo |
| Oyster Point Pharma, INC. | $42.51 | 2023 | Tyrvaya |
| Biotissue Holdings INC. | $33.31 | 2021-2024 | |
| Glaukos Corporation | $26.87 | 2024 | Idose |
| Omeros Corporation | $22.92 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $21.96 | 2023 | Veritas Vision System |
| Shire North American Group INC | $18.68 | 2019 | |
| Horizon Therapeutics Plc | $16.90 | 2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $15.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.